Tumor necrosis factor receptor-associated factor 2 (TRAF2)

Tumor necrosis factor receptor-associated factor 2 (TRAF2) is an intracellular adapter protein encoded by the TRAF2 gene. It belongs to the family of tumor necrosis factor receptor associated factors (TRAFs), which mediate signal transduction from members of the tumor necrosis factor receptor superfamily as well as other immune-related receptors such as interleukin receptors. TRAF2 possesses E3 ubiquitin ligase activity and interacts with various proteins—including plasma membrane receptors, kinases, phosphatases, other E3 ligases like cIAPs—playing a central role in activating transcription factors such as NF-kappaB and JNK/MAPK8 pathways.[5][7] It forms complexes with other adapter proteins like TRAF1, facilitating anti-apoptotic signals from TNFRs through recruitment of inhibitor-of-apoptosis proteins (cIAPs) that inhibit caspase activation.[3][5] Through these mechanisms it regulates key cellular processes including inflammation, cell death/survival decisions, immunity against pathogens/infections,[4] cancer development/progression,[7] ER stress responses,[4] autophagy,[4] and more. Structurally characterized domains include a coiled-coil region followed by a conserved C-terminal "TRAF-C" domain responsible for self-association into trimers required for high-avidity binding to activated trimeric cytokine receptors.[3] Dysregulation or mutation within this pathway has been implicated in various diseases including cancers (where it can act either pro-tumorigenically or suppressively depending on context), inflammatory conditions due to aberrant immune signaling,[7] hematologic malignancies such as multiple myeloma,[7],and infectious disease susceptibility due to altered host defense mechanisms.[4] While not currently targeted directly by approved therapeutics due to its central role across many critical cellular functions—and thus significant safety concerns—its importance makes it an area of active research interest both mechanistically and potentially therapeutically via indirect modulation within its network.

Other names

TNF receptor-associated factor 2TRAF-2TNFRSF signal transducer TRAF2

Drugs that affect the TNFR signaling axis may influence TRAF2-mediated pathways by: - Blocking ligand-receptor interactions upstream of TRAF2 (e.g., anti-TNF antibodies) TRAF2 itself is not a direct drug target but is essential for the assembly of signaling complexes leading to NF-kappaB activation and inhibition of apoptosis in response to TNFR stimulation.